Catalyst Wire Dossier Catalyst Wire Dossier

REGN7945

· Regeneron Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for REGN7945, covering 2026-04-13 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

See pricing